| Literature DB >> 33997676 |
Tahmina Hossain1, Heather S Deter2, Eliza J Peters1, Nicholas C Butzin1.
Abstract
Antibiotic resistance is a growing problem, but bacteria can evade antibiotic treatment via tolerance and persistence. Antibiotic persisters are a small subpopulation of bacteria that tolerate antibiotics due to a physiologically dormant state. Hence, persistence is considered a major contributor to the evolution of antibiotic-resistant and relapsing infections. Here, we used the synthetically developed minimal cell Mycoplasma mycoides JCVI-Syn3B to examine essential mechanisms of antibiotic survival. The minimal cell contains only 473 genes, and most genes are essential. Its reduced complexity helps to reveal hidden phenomenon and fundamental biological principles can be explored because of less redundancy and feedback between systems compared to natural cells. We found that Syn3B evolves antibiotic resistance to different types of antibiotics expeditiously. The minimal cell also tolerates and persists against multiple antibiotics. It contains a few already identified persister-related genes, although lacking many systems previously linked to persistence (e.g. toxin-antitoxin systems, ribosome hibernation genes).Entities:
Keywords: Microbiofilms; Microbiology
Year: 2021 PMID: 33997676 PMCID: PMC8091054 DOI: 10.1016/j.isci.2021.102391
Source DB: PubMed Journal: iScience ISSN: 2589-0042
Figure 1Tolerance permits antibiotic resistance
Persisters survive antibiotic treatment, reestablish the population when antibiotics are removed, and increase the odds of gaining resistance. Presumably, viable but nonculturable cells (VBNCs) can do this too (although we did not study VBNCs in this work).
Mutation of Mycoplasma mycoides JCVI-Syn3B, and Whole Genome Sequence (WGS) analysis identified the mutations (bold and underlined)
| Syn3B | Intergenic mutation | Mutation positions | Genotype change | Amino acid substitution | Gene | Gene annotation |
|---|---|---|---|---|---|---|
| Parent∗ | ||||||
| P026 | 9 | 547 | Ala → Thr | Chromosomal replication initiator protein DnaA | ||
| 274928 | TA | Tyr → Tyr | Dihydroxyacetone kinase | |||
| PK07-L1 | 8 | 479174 | Pro → Thr | DNA-directed RNA polymerase subunit beta | ||
| 3322 | G | Gly → Glu | ||||
| PK07-L2 | 8 | 479174 | Pro → Thr | |||
| 3322 | G | Gly → Glu | ||||
| PS04-L1 | 4 | 101452 | A | Lys → Arg | 30S ribosomal protein S12 | |
| 33,652 | Gly → Arg | Unknown | ||||
| PS04-L2 | 3 | 101452 | A | Lys → Arg | ||
| 147803 | A | Ser → Ile; | 30S ribosomal protein S4 | |||
| 33,652 | Gly → Arg | |||||
| PC06-L1 | 4 | 7735 | Glu→ Lys | DNA gyrase subunit A | ||
| 305613 | Asp→ Asn | DNA topoisomerase 4 subunit A | ||||
| PC06-L2 | 4 | 7735 | Glu→ Lys | |||
| 305613 | Asp→ Asn | |||||
| 304707 | G | Asp→ Ala | DNA topoisomerase 4 subunit B | |||
| 33,652 | Gly → Arg | |||||
| PSC09-L1 | 4 | 7725 | AG | Ser→ Arg | ||
| 101452 | A | Lys → Arg | ||||
| 33,652 | Gly → Arg | |||||
| 305602 | A | Ser→ Ile | ||||
| PSC09-L2 | 4 | 7725 | AG | Ser→ Arg | ||
| 101452 | A | Lys → Arg | ||||
| 33,652 | Gly → Arg | |||||
| 305602 | A | Ser→ Ile | ||||
All antibiotic-resistant mutant strains were named based on the number of passes (P) in a specific antibiotic (K: Ksg, S: Strep, C: Cip, SC: Strep-Cip). All antibiotic-resistant mutants were selected from two separate evolutionary lineages, and named L1 for lineage 1 or L2 for linage 2.
∗Parent: High growth rate mutant parent to all of the strains in the table.
+Mutated genes are likely to be functional, although the mutated genes' functionality has not been tested in this study.
Mutation in the non-coding DNA sequences located between genes.
Genomic position numberings correspond to Mycoplasma mycoides JCVI-Syn3B and P026 (CP053944).
Synonymous mutation: mutation does not change in the encoded amino acid sequence.
Figure 2Population decay during antibiotic treatment shows Syn3B persistence
(A) A simplified model of population decay having two phases: short-term tolerance phase and long-term tolerance phase. Both phases contain heterogeneous populations. The short-term tolerant phase contains susceptible cells, slow-growing cells, transient tolerant cells, persister and viable but nonculturable cells (VBNCs). Transient tolerant cells survive longer than fast-growing susceptible cells, while transient tolerant cells die quicker than the persisters and VBNCs (VBNCs and persisters were not distinguished in this study). The long-term tolerant phase contains both persisters and VBNCs.
(B) Population decay of Syn3B (parent strain). Overnight cultures of Syn3B (parent strain) were grown to stationary phase, diluted to 1:10, and then treated with streptomycin (100 μg/mL) or ciprofloxacin (1 μg/mL) and sampled over time. Error bars represent SEM (n ≥ 3).
(C and D) Population decay of Syn3B P026. Syn3B P026 cells were treated with streptomycin (100 μg/mL) or ciprofloxacin (1 μg/mL) and sampled over time. (C) Stationary phase cells were diluted 1:10 into fresh media containing antibiotics. Error bars represent SEM (n ≥ 6). (D) Exponential phase cells were treated with streptomycin (100 μg/mL) or ciprofloxacin (1 μg/mL) and sampled over time. Error bars represent SEM (n ≥ 3). There is 100% survival at time zero because percent survival is determined by the surviving CFU/ml compared to the CFU/ml at time zero.
Figure 3Co-treatment of bactericidal and bacteriostatic antibiotic increases survival percentage
The co-treatment of bactericidal antibiotic (streptomycin (Strep) or ciprofloxacin (Cip)) with a bacteriostatic antibiotic (chloramphenicol (Cm)) shows increased survival of cells for 24 h (left) and 48 h (right) in Syn3B P026. Error bars represent SEM (n ≥ 3). ∗p < 0.05. ∗∗p < 0.01.
Syn3B contains genes previously shown to be related to E.coli persistence and tolerance
| Gene | Protein/RNA | Major function | REF |
|---|---|---|---|
| Chaperon | Global regulator | ( | |
| Phosphate-specific transport system accessory protein | Global regulator | ||
| Exodeoxyribonuclease | DNA mismatch repair and recombination | ( | |
| Endonuclease | SOS response | ( | |
| GTP pyrophosphokinase | Stringent response | ( | |
| Protease | Protease | ( | |
| Serine hydroxymethyltransferase | Metabolism | ( | |
| ATP synthase | ATP synthesis | ( | |
| UTP–glucose-1-phosphate uridylyltransferase | Lipopolysaccharide precursor synthesis | ( | |
| tRNA modification GTPase; Elongation factor P; Endoribonuclease | Translation | ( | |
| Transfer messenger RNA (tmRNA); Small Protein B | Trans-translation | ( |
In Bigger's 1944 paper, he identified cells that survived antibiotics longer, named them persisters, and listed 10 characteristics of the persister subpopulation
| Syn3B persisters | ||
|---|---|---|
| 1. | An antibiotic failed to kill a small population of bacteria. | Multiple antibiotics failed to kill a small population of Syn3B. |
| 2. | Persisters are a small population initially present in the population. | Syn3B contains a small persister subpopulation among the susceptible population. |
| 3. | Persister can be induced or changed based on the environment. | The persistence (surviving population) level is different when the culture originated from a stationary phase or exponential phase. |
| 4. | This was not tested for Syn3B persisters. | |
| 5. | Bacteriocidal concentrations of an antibiotic killed the susceptible population, but not persisters. | The Syn3B susceptible population was killed by bacteriocidal concentrations of more than one antibiotic type, but persisters were not. |
| 6. | Persisters are likely insensitive to an antibiotic because they are dormant and non-dividing. The antibiotic used, penicillin, kills bacteria only when they divide. | Syn3B persisters also appear to be dormant and likely non-dividing, because the antibiotics used are more effective against dividing cells. |
| 7. | Descendants of persisters are no more resistant to an antibiotic than the original population. | Syn3B descendants of persisters are no more resistant to an antibiotic than the original population. |
| 8. | When the antibiotic is destroyed, the majority of persisters will emerge and grow normally. | Syn3B persisters grew once the antibiotic was removed or diluted below the MIC. |
| 9. | The antibiotic prolongs the dormant phase but not indefinitely. | Syn3B persisters continue to die, but slowly, the longer they are exposed to antibiotics. There is no plateau but a slow decline in cell death. |
| 10. | This was not tested for Syn3B persisters. Syn3B persisters continue to die, but slowly, the longer they are exposed to antibiotics. There is no plateau but a slow decline in cell death. |
Syn3B meets 9 of 10 characteristics defined by Bigger. Left column: summary of Bigger's definition. Right column: similar characteristics of Syn3B persisters. We provided no evidence related to point 4 but observed a similar phenotype as Bigger to support point 10.
Points 4 and 10 were untested hypotheses of Bigger and were not tested in our work.